BR112017009168A2 - derivado de tionucleosídeo ou sal deste e composição farmacêutica - Google Patents

derivado de tionucleosídeo ou sal deste e composição farmacêutica

Info

Publication number
BR112017009168A2
BR112017009168A2 BR112017009168A BR112017009168A BR112017009168A2 BR 112017009168 A2 BR112017009168 A2 BR 112017009168A2 BR 112017009168 A BR112017009168 A BR 112017009168A BR 112017009168 A BR112017009168 A BR 112017009168A BR 112017009168 A2 BR112017009168 A2 BR 112017009168A2
Authority
BR
Brazil
Prior art keywords
salt
pharmaceutical composition
thionucleoside derivative
thionucleoside
tumor
Prior art date
Application number
BR112017009168A
Other languages
English (en)
Other versions
BR112017009168B1 (pt
Inventor
Nakagawa Daisuke
Kuniyoshi Hidenobu
Matsumoto Takuya
Yoshimitsu Yuji
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of BR112017009168A2 publication Critical patent/BR112017009168A2/pt
Publication of BR112017009168B1 publication Critical patent/BR112017009168B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

resumo ?derivado de tionucleosídeo ou sal deste e composição farmacêutica? são divulgados um composto e uma composição farmacêutica que exibem uma eficácia de fármaco excelente contra um tumor em particular um tumor que tem resistência adquirida à gencitabina. especificamente, é fornecido um derivado de tionucleosídeo representado pela fórmula geral [1] (na fórmula, r1 representa um grupo hidroxila que pode ser protegido, um grupo alcóxi c que pode ser substituído, ou semelhantes; r2 representa um grupo alcóxi c que pode ser substituído, um grupo cicloalcóxi c que pode ser substituído, ou semelhantes; e r3 representa um átomo de hidrogênio ou semelhantes); ou um sal deste. além disso, é fornecida uma composição farmacêutica contendo um tal derivado de tionucleosídeo ou um sal deste.
BR112017009168-2A 2014-10-31 2015-11-02 Derivado de tionucleosídeo ou sal deste, composição farmacêutica que compreende o mesmo e uso da dita composição para tratar câncer pancreático BR112017009168B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-222527 2014-10-31
JP2014222527 2014-10-31
PCT/JP2015/080885 WO2016068341A1 (ja) 2014-10-31 2015-11-02 チオヌクレオシド誘導体またはその塩および医薬組成物

Publications (2)

Publication Number Publication Date
BR112017009168A2 true BR112017009168A2 (pt) 2017-12-19
BR112017009168B1 BR112017009168B1 (pt) 2022-10-04

Family

ID=55857673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009168-2A BR112017009168B1 (pt) 2014-10-31 2015-11-02 Derivado de tionucleosídeo ou sal deste, composição farmacêutica que compreende o mesmo e uso da dita composição para tratar câncer pancreático

Country Status (11)

Country Link
US (2) US10059734B2 (pt)
EP (1) EP3214090B1 (pt)
JP (1) JP6353922B2 (pt)
KR (1) KR102056135B1 (pt)
CN (1) CN107148423B (pt)
AU (1) AU2015337512B2 (pt)
BR (1) BR112017009168B1 (pt)
CA (1) CA2966138C (pt)
RU (1) RU2669806C1 (pt)
TW (1) TWI678373B (pt)
WO (1) WO2016068341A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2883866B1 (en) 2012-08-13 2019-02-27 FUJIFILM Corporation INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-beta-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
RU2752172C2 (ru) 2016-08-31 2021-07-23 Фуджифилм Корпорэйшн Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
US10787477B2 (en) 2016-12-22 2020-09-29 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of 4′-thio-2′-fluoronucleoside phosphamide compound and preparation method therefor and use thereof
CN111491634A (zh) 2017-07-31 2020-08-04 詹纽瑞治疗公司 有机磷酸酯衍生物
EP3677267A4 (en) * 2017-09-01 2021-06-02 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
MX2018002611A (es) 2018-01-29 2019-07-30 Fujifilm Corp Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.
EP3758495A4 (en) * 2018-03-02 2021-12-01 January Therapeutics, Inc. COMPOSITIONS OF NANOPARTICLES
CN112105624B (zh) * 2018-03-09 2023-09-22 美迪维尔公司 使用(2,2-双羟甲基)亚甲基环丙烷核苷酸治疗癌症
KR20210005638A (ko) * 2018-04-19 2021-01-14 써던 리서취 인스티튜트 암의 치료를 위한 4'-티오-뉴클레오타이드 및 -뉴클레오사이드 전구약물
CN112512529B (zh) 2018-07-27 2024-06-18 富士胶片株式会社 环戊烯嘌呤衍生物或其盐
WO2020108343A1 (zh) * 2018-11-28 2020-06-04 四川科伦博泰生物医药股份有限公司 以4'-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
KR20220039748A (ko) * 2019-07-30 2022-03-29 주식회사 피노바이오 암 치료용 디뉴클레오티드 화합물 및 그의 의약 용도
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
WO2021226559A1 (en) 2020-05-08 2021-11-11 Tonix Pharmaceuticals, Inc. Radio-and chemo-protective compounds
EP4378466A1 (en) 2021-07-29 2024-06-05 FUJIFILM Corporation Pharmaceutical composition and anti-tumor agent for tumors that have at least either impaired bap1 or pbrm1 function

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3243425A (en) 1962-10-29 1966-03-29 Purdue Research Foundation Novel sulfur-containing compounds
JPS53119810A (en) 1977-03-25 1978-10-19 Mitsubishi Chem Ind Ltd Preparation of aldehyde chloride
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4220774A (en) 1978-10-26 1980-09-02 Omnium Chimique Vincadifformine synthesis process
JPS5692239A (en) 1979-12-27 1981-07-25 Sagami Chem Res Center Preparation of 5-oxohexyl compound
US4803272A (en) 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
IE74701B1 (en) 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
JP3138834B2 (ja) 1991-12-26 2001-02-26 生化学工業株式会社 フコピラノース類縁体の製造方法およびその合成中間化合物
GB9218810D0 (en) 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
US5811408A (en) 1994-07-12 1998-09-22 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides
JPH0853490A (ja) 1994-08-09 1996-02-27 Yamasa Shoyu Co Ltd ２’−デオキシ−２’，２’−ジハロゲノ−４’−チオヌクレオシド
ES2182061T3 (es) * 1996-04-09 2003-03-01 Yamasa Corp 1 - (2 - desoxi - 2 - fluor-4- tio-beta-d arabinofuranosil)citosina.
JP4202327B2 (ja) 1996-04-09 2008-12-24 ヤマサ醤油株式会社 １−（２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノシル）シトシン
US6103707A (en) 1996-04-09 2000-08-15 Yamasa Corporation 9-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)purine derivatives
HUP9601756A3 (en) 1996-06-25 1999-05-28 Richter Gedeon Vegyeszet New anticoagulant glycosides and pharmaceutical compositions containing them
JP4087471B2 (ja) 1997-03-31 2008-05-21 大日本印刷株式会社 表面プラズモン共鳴バイオセンサー用測定チップ及びその製造方法
HUP9702348A3 (en) 1997-12-04 2000-12-28 Richter Gedeon Vegyeszet New anticoagulant glycosides and pharmaceutical conew anticoagulant glycosides and pharmaceutical compositions containing them mpositions containing them
WO1999043690A1 (fr) 1998-02-25 1999-09-02 Rational Drug Design Laboratories Compose de l-4'-arabinofuranonucleoside et composition medicinale le contenant
ATE531376T1 (de) 1998-07-23 2011-11-15 Southern Res Inst Verwendung von thioarabinofuranosyl-verbindungen
WO2001066118A1 (en) 2000-03-08 2001-09-13 Southern Research Institute 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof
KR100426030B1 (ko) 2000-07-22 2004-04-03 (주) 한켐 락톤계 당화합물에서의 키랄성 전환방법
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
AU2002322325A1 (en) 2001-06-22 2003-01-08 Emory University Beta-2'-or 3'-halonucleosides
JP2003172990A (ja) 2001-08-03 2003-06-20 Fuji Photo Film Co Ltd ハロゲン化銀乳剤及びハロゲン化銀写真感光材料
KR20050056194A (ko) 2002-08-09 2005-06-14 다이쇼 세이야꾸 가부시끼가이샤 선택적인 아릴 5-티오-β-Ｄ-알도헥소피라노시드의 제조방법
AU2003200960B2 (en) 2002-09-18 2005-01-06 Mackinnon, Sebastian Mr System for Ordering, Tracking and Payment of Goods and Services
WO2004100891A2 (en) 2003-05-12 2004-11-25 Purdue Research Foundation Cytotoxic indeno and isoindoloisoquinolones
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
WO2004106352A1 (ja) 2003-05-29 2004-12-09 Taisho Pharmaceutical Co., Ltd. アルドヘキソピラノース中間体の製造法
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5317257B2 (ja) * 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
JP2006335737A (ja) 2005-06-03 2006-12-14 Ihara Nikkei Kagaku Kogyo Kk ベンゾ［ｃ］ヘテロ５員環化合物の製造方法
WO2007056596A2 (en) * 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
CN101336247B (zh) * 2005-12-09 2013-01-23 豪夫迈·罗氏有限公司 抗病毒核苷
WO2007068113A1 (en) 2005-12-16 2007-06-21 Mcgill University 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
CN100513395C (zh) 2006-04-17 2009-07-15 中国科学院化学研究所 一种制备多羟基环状硝酮的方法
US7749983B2 (en) 2006-05-03 2010-07-06 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
CN101200463B (zh) 2007-12-11 2011-06-22 复旦大学 全酰化-4-硫代-d-核糖及其制备方法
US8859589B2 (en) 2008-03-12 2014-10-14 Southern Research Institute Use of 4′-thio-2′-deoxynucleosides as anti orthopoxvirus agents
CN101880287B (zh) 2009-05-05 2012-07-25 上海医药工业研究院 一类四氢噻吩核苷类似物的中间体化合物及其制备方法
TWI476204B (zh) 2009-12-18 2015-03-11 Libramedicina Inc 製備經取代之１－Ｏ－醯基－２－脫氧－２－氟－４－硫－β－Ｄ－阿拉伯呋喃糖的製程
AP3584A (en) * 2010-09-22 2016-02-09 Alios Biopharma Inc Substituted nucleotide analogs
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
JP5776564B2 (ja) 2012-01-20 2015-09-09 日本精工株式会社 ワーク処理装置、及びワーク処理方法
SG10201603288XA (en) 2012-03-28 2016-05-30 Fujifilm Corp Salt Of 1-(2-Deoxy-2-Fluoro-4-Thio-beta-D-Arabinofuranosyl)Cytosine
US20140029864A1 (en) 2012-07-30 2014-01-30 Dror Reif Compression encoding and decoding method and apparatus
EP2883866B1 (en) 2012-08-13 2019-02-27 FUJIFILM Corporation INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-beta-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6204223B2 (ja) 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
CA2966138A1 (en) 2016-05-06
CA2966138C (en) 2020-01-14
US20170233429A1 (en) 2017-08-17
WO2016068341A1 (ja) 2016-05-06
US20180319834A1 (en) 2018-11-08
KR102056135B1 (ko) 2019-12-16
US10059734B2 (en) 2018-08-28
EP3214090B1 (en) 2020-08-19
US10385089B2 (en) 2019-08-20
EP3214090A1 (en) 2017-09-06
RU2669806C1 (ru) 2018-10-16
AU2015337512A1 (en) 2017-05-18
BR112017009168B1 (pt) 2022-10-04
KR20170058436A (ko) 2017-05-26
EP3214090A4 (en) 2017-09-13
JPWO2016068341A1 (ja) 2017-08-10
TWI678373B (zh) 2019-12-01
TW201619179A (zh) 2016-06-01
CN107148423A (zh) 2017-09-08
AU2015337512B2 (en) 2018-09-06
CN107148423B (zh) 2021-07-30
JP6353922B2 (ja) 2018-07-04

Similar Documents

Publication Publication Date Title
BR112017009168A2 (pt) derivado de tionucleosídeo ou sal deste e composição farmacêutica
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016017747A2 (pt) Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo
BR112016002083A2 (pt) composto tetrazolinona e uso para o mesmo
BR112017027951A2 (pt) composto inibitório de brk
BR112015001121A2 (pt) composição para controle de doença de planta e aplicação para a mesma
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
BR112014000665B8 (pt) composto, composição farmacêutica, agente antimicrobiano, e, uso de um composto
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
BR112016007427A2 (pt) compostos de pirazol-amida e usos dos mesmos
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
BR112012032462A2 (pt) agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
BR112018017303A2 (pt) composto tipo piridazinona ou seu sal, e herbicida compreendendo o mesmo
BR112013017520A2 (pt) composto bicíclico ou sal do mesmo
MX2020007152A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2015, OBSERVADAS AS CONDICOES LEGAIS